pharmaceutical industry

Stories 41 - 60 | << Prev   Next >>

Pharma Company Still Hasn't Reversed 5,000% Price Hike

Even though Martin Shkreli said they would backtrack

(Newser) - Two weeks ago, Martin Shkreli, the controversial CEO of Turing Pharmaceuticals, said that, following much public pressure, he would dial back his company's 5,000% price hike on a toxoplasmosis drug. But Daraprim, which jumped from $13.50 to $750 per pill, still costs the same amount, Business Insider... More »

Punk Label Boots Drug CEO Over Un-Punk Price Gouging

'It blindsided and upset us on every level'

(Newser) - Former hedge-fund manager Martin Shkreli has been booted from the punk label he was bankrolling for doing one of the most un-punk things possible: jacking up the price of the drug that treats the potentially deadly parasitic infection toxoplasmosis by 5,000%, the Guardian reports. Shkreli became infamous this week... More »

Drug CEO Caves, Will Drop Price of $750 Pill

Martin Shkreli says people misunderstand the issue

(Newser) - The drug company CEO called the "most hated man in America right now" by the BBC says he's misunderstood—but that he'll lower the price of Daraprim in response to the firestorm of criticism . "There were mistakes made with respect to helping people understand why we... More »

Here's How Price-Gouging Drug CEO Says He Sleeps at Night

'You know, Ambien' suggests Martin Shkreli is A-OK with exorbitant price hike

(Newser) - Price gouging for a tuberculosis drug may have been walked back , but the CEO of another pharmaceutical company is standing firm with his decision to drastically raise the price of a drug that treats the potentially deadly parasitic infection toxoplasmosis. Turing Pharmaceutical's Martin Shkreli—an ex-hedge fund manager who... More »

Drug's Price Hike From $16 to $360 Doesn't Last

But CEO behind another huge price hike stands firm

(Newser) - A huge hike in the price of a tuberculosis drug has been rolled back amid an outcry over the 5,000% leap in the price of another drug. A nonprofit group affiliated with Purdue University sold the rights to cycloserine to Rodelis Therapeutics on Aug. 19 , but it demanded them... More »

Drug's Price Changed From $13.50 a Tablet to $750

Daraprim move doesn't go over well

(Newser) - "This isn't the greedy drug company trying to gouge patients, it is us trying to stay in business. It really doesn't make sense to get any criticism for this." The "this" Martin Shkreli is referring to is the price hike his company instituted after it... More »

Drug Maker Fights for Awareness of Disorder It Can Cash In On

Shire just got FDA approval for binge eating disorder drug

(Newser) - Binge eating disorder, which gained American Psychiatric Association recognition in 2013, isn't particularly well-known. That's not good for a pharmaceutical company like Shire, maker of an ADHD drug called Vyvanse, which was recently approved by the FDA for marketing in the treatment of binge eating. Lately, Shire has... More »

California Sues: Big Pharma Created Addicts With Lies

Lawsuit alleges slick marketing got people hooked on opioid painkillers

(Newser) - The makers of strong painkillers like OxyContin have created a "population of addicts" with a "campaign of deception" about the risks the drugs carry, two California counties charge in a lawsuit filed on behalf of the whole state. Orange and Santa Clara counties are suing five large makers... More »

Glaxo: We'll Stop Paying Doctors to Hawk Our Drugs

It's a big change in pharma industry

(Newser) - In what "appears to be a first for a major drug company," according to the New York Times , GlaxoSmithKline will stop paying doctors to promote its drugs under a new plan to be completed by 2016. The company's pharmaceutical sales reps will also no longer be paid... More »

Diagnosed With ADHD? You May Have Been Sold a Lie

Drug companies target parents through false advertising: report

(Newser) - The diagnosis of attention deficit hyperactivity disorder has itself become hyperactive, with doctors handing out too many pills, ads creating unrealistic expectations, and drug companies downplaying side effects like insomnia and mood swings, the New York Times reports. "The numbers make it look like an epidemic. Well, it's... More »

Birth Control Called 'Deadly,' Still Sells Bigtime

NuvaRing known to cause scary blood clots

(Newser) - A potentially deadly contraceptive called NuvaRing is still on the US market—but why? That's what Marie Brenner aimed to find out in Vanity Fair . She learned that NuvaRing maker Merck made $623 million selling NuvaRing last year, despite users who developed terrifying blood clots and filed roughly 3,... More »

The New Guides on Statins Are Insane

Giving cholesterol drugs to healthy Americans is not the answer, 2 experts argue

(Newser) - The American Heart Association and the College of Cardiology want millions more healthy Americans to take cholesterol-lowering statins , which might sound like a good idea "if statins actually offered meaningful protection from heart disease; if they helped people live longer or better; and if they had minimal adverse side... More »

US Asthma Sufferers Coughing Up More Cash

Costs for asthma sufferers have skyrocketed, resulting in preventable deaths

(Newser) - The New York Times continues its "US health care costs are way higher than the rest of the world" series (see previously here and here ) with a look at the most common chronic disease in America: asthma. According to the Times, it's becoming an increasingly pricey affliction... More »

How Big Pharma Keeps Meth Labs Cooking

Lobbyists are battling attempts to legislate cold and allergy medicines

(Newser) - It's pretty easy to make meth at home, and Big Pharma seems intent on keeping it that way, Mother Jones reports. The so-called "one pot" method of meth production relies on pseudoephedrine , a common ingredient in medicines like Sudafed and Claritin D. So two states—Oregon and Mississippi—... More »

FDA: Ameridose Is Rife With Contamination Issues

Bugs, leaks found inside drug firm linked to outbreak

(Newser) - The FDA's monthlong inspection of Ameridose, a firm with the same founders as the pharmacy linked to a deadly meningitis outbreak, has produced a long and troubling list of contamination issues, the AP reports. Inside the company's drug-making facility, federal inspectors found leaky, cracked walls and ceilings, insects... More »

Glaxo Buying Human Genome Sciences

After big drug failure in 2011, Human Genome failed to find higher bid

(Newser) - British pharma giant GlaxoSmithKline is poised to announce a $2.8 billion takeover of Human Genome Sciences, perhaps as early as today, reports Reuters . US-based Human Genome, which uses the human DNA sequence to develop drugs, balked at Glaxo's original $2.6 billion offer and said it would go... More »

America's New Jobless: Glut of Science PhDs

Science jobs declining as PhDs surging

(Newser) - President Obama, like a lot of politicians and pundits, likes to say that America's future lies with science, advocating for more young people to go into research. But the truth is that the supply of PhDs has been vastly outpacing the job market for years, resulting in a glut,... More »

FDA OKs First Diet Pill in 13 Years

Arena's Belviq is intended for the obese

(Newser) - For the first time in 13 years, the FDA has approved an anti-obesity pill. The medication, called Belviq, targets a section of the brain responsible for regulating hunger, reports Bloomberg . Sales could hit $2 billion in 2020, predicts an analyst. “Two-thirds of the people in this country are overweight... More »

Drug Company Employee: Don't Believe Our Studies

Anonymous author in medical journal warns of bogus research

(Newser) - Bear this in mind the next time a drug company touts a serious study proclaiming the wonders of its product: A former employee of a "major" pharmaceutical company has written an essay in the British Medical Journal warning that the industry's scientific-sounding studies are sometimes rigged. “We... More »

White House Made Deal With Big Pharma on Health Bill

Whether that's good or bad is open for debate

(Newser) - The White House cut a deal with the pharmaceutical industry to get health-care reform passed, a revelation getting renewed attention thanks to emails released by House Republicans, reports the New York Times . In one from 2009, Obama adviser Nancy-Ann DeParle tells a top industry lobbyist that the administration has agreed... More »

Stories 41 - 60 | << Prev   Next >>
We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.